Rhythm Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Rhythm Pharmaceuticals generated cash of -$136,157,000, which is more than the previous year. Cash used in financing activities reached the amount of $74,368,000 last year. Net change in cash is therefore -$67,596,000.
Cash Flow
| 2013 | -19.15M | -5.12M | 19.88M |
|---|---|---|---|
| 2015 | -6.97M | -17K | 41.71M |
| 2016 | -23.21M | -5.11M | 0 |
| 2017 | -29.46M | -110.04M | 167.2M |
| 2018 | -62.05M | -87.14M | 164.68M |
| 2019 | -122.75M | -27.97M | 163.47M |
| 2020 | -121.98M | 158.53M | 2.00M |
| 2021 | -146.00M | -62.15M | 166.48M |
| 2022 | -173.42M | 28.02M | 213.82M |
| 2023 | -136.15M | -5.66M | 74.36M |
RYTM Cash Flow Statement (2013 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 128.00M | 59.57M | 101.25M | 62.69M | 49.94M | 34.46M | 6.54M | 34.86M | 152K | 11.76M |
Operating activities | ||||||||||
Net income | -184.67M | -181.11M | -69.61M | -133.99M | -140.72M | -74.06M | -33.70M | -25.87M | -11.07M | -21.43M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.75M | 1.67M | 1.15M | 690K | 834K | 442K | 223K | 144K | 0 | 20K |
Stock-based compensation expense | 32.55M | 19.83M | 20.80M | 17.45M | 11.87M | 0 | 2.27M | 1.16M | 298K | 0 |
| Deferred income tax benefit | 32.55M | 19.83M | 20.80M | 17.45M | 11.87M | 0 | 2.27M | 1.16M | 298K | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -8.64M | -5.19M | -1.25M | 0 | 0 | 0 | 0 | 0 | -60K | 0 |
Inventories | -5.70M | -2.80M | -11K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 14.77M | 1.54M | 18.31M | 10.50M | 10.50M | 6.95M | 1.94M | 467K | 3.83M | -780K |
Cash generated by operating activities | -136.15M | -173.42M | -146.00M | -121.98M | -122.75M | -62.05M | -29.46M | -23.21M | -6.97M | -19.15M |
Investing activities | ||||||||||
Purchases Of Investments | -354.91M | -251.93M | -524.97M | -86.86M | -295.82M | -248.59M | -126.91M | -15.22M | 0 | -28.74M |
Investments In Property Plant And Equipment | -47K | -4.28M | -5.43M | -214K | -3.38M | -722K | -133K | -1.05M | -17K | 0 |
Acquisitions Net | 0 | 4M | 100M | -158.74M | 24.58M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -5.66M | 28.02M | -62.15M | 158.53M | -27.97M | -87.14M | -110.04M | -5.11M | -17K | -5.12M |
Financing activities | ||||||||||
Common Stock Issued | 48.87M | 131.11M | 166.48M | 161.35M | 161.35M | 0 | 125.65M | 0 | 39.61M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 74.36M | 213.82M | 166.48M | 2.00M | 163.47M | 164.68M | 167.2M | 0 | 41.71M | 19.88M |
Net Change In Cash | -67.59M | 68.42M | -41.68M | 38.56M | 12.75M | 15.48M | 27.69M | -28.32M | 34.71M | -4.40M |
Cash at end of period | 60.40M | 128.00M | 59.57M | 101.25M | 62.69M | 49.94M | 34.23M | 6.54M | 34.86M | 7.36M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |